PriceTargets.com logo

Phathom Pharmaceuticals - PHAT Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $23.43
  • Forecasted Upside: 167.76%
  • Number of Analysts: 8
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 1 Strong Buy Ratings
$8.75 As of 07/31/2026 05:00 PM ET
▼ -0.28 (-3.10%)

This chart shows the closing price for PHAT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Phathom Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PHAT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PHAT

Analyst Price Target is $23.43
▲ +167.76% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Phathom Pharmaceuticals in the last 3 months. The average price target is $23.43, with a high forecast of $28.00 and a low forecast of $18.00. The average price target represents a 167.76% upside from the last price of $8.75.

This chart shows the closing price for PHAT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 8 investment analysts is to moderate buy stock in Phathom Pharmaceuticals. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/8/2025
  • 1 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2025
  • 1 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2025
  • 1 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/5/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
2/3/2026
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/4/2026
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
7/3/2026
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/2/2026

Latest Recommendations

  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/31/2026Craig HallumReiterated RatingBuy ➝ Buy$20.00
7/31/2026GuggenheimLower TargetBuy ➝ Buy$25.00 ➝ $22.00
7/31/2026HC WainwrightReiterated RatingBuy ➝ Buy$26.00
7/30/2026Needham & Company LLCLower TargetBuy ➝ Buy$28.00 ➝ $22.00
7/17/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
6/17/2026HC WainwrightReiterated RatingBuy ➝ Buy$26.00
4/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
3/27/2026BarclaysUpgradeEqual Weight ➝ Overweight$16.00 ➝ $18.00
2/27/2026GuggenheimBoost TargetBuy ➝ Buy$20.00 ➝ $25.00
2/26/2026Stifel NicolausSet Target$28.00
1/22/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
1/14/2026Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight
12/11/2025Raymond James FinancialInitiated CoverageStrong-Buy$28.00
12/11/2025Raymond James FinancialInitiated CoverageStrong-Buy$28.00
12/8/2025BarclaysInitiated CoverageEqual Weight$16.00
12/8/2025BarclaysUpgradeHold
10/31/2025Craig HallumReiterated RatingBuy ➝ Buy$22.00
10/31/2025HC WainwrightBoost TargetBuy ➝ Buy$20.00 ➝ $26.00
10/30/2025GuggenheimReiterated RatingBuy ➝ Buy$20.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
6/9/2025Craig HallumBoost TargetBuy ➝ Buy$12.00 ➝ $17.00
6/9/2025HC WainwrightReiterated RatingBuy ➝ Buy$20.00
6/6/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$28.00
5/2/2025The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$10.00 ➝ $5.00
5/2/2025GuggenheimLower TargetBuy ➝ Buy$18.00 ➝ $12.00
5/2/2025HC WainwrightLower TargetBuy ➝ Buy$28.00 ➝ $20.00
4/21/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
4/17/2025The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$12.00 ➝ $10.00
4/9/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
4/2/2025GuggenheimReiterated RatingBuy ➝ Buy
4/2/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
3/10/2025The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$18.00 ➝ $12.00
3/7/2025GuggenheimSet Target$18.00
3/7/2025Craig HallumReiterated RatingBuy ➝ Buy
3/7/2025HC WainwrightReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
3/6/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
2/25/2025Cantor FitzgeraldUpgradeStrong-Buy
2/14/2025Cantor FitzgeraldInitiated CoverageOverweight$23.00
1/10/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
12/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
12/11/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
9/13/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
9/6/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
8/30/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
8/19/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
8/12/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
8/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
8/9/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$10.00 ➝ $12.00
7/26/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
7/19/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
7/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
7/8/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
6/28/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
6/21/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
6/14/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
6/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
5/31/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
5/24/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
5/17/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00
5/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$28.00
5/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00
5/3/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00
5/3/2024Stifel NicolausInitiated CoverageBuy$24.00
4/26/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00
4/19/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00
4/11/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00
4/1/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00
3/22/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00
3/15/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00
2/23/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00
2/16/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00
2/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$26.00
1/5/2024Needham & Company LLCBoost TargetBuy ➝ Buy$23.00 ➝ $26.00
11/10/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$23.00
11/3/2023The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$9.00 ➝ $10.00
9/27/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$23.00
8/11/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$23.00
8/9/2023HC WainwrightInitiated CoverageBuy ➝ Buy$28.00
5/11/2023EvercoreUpgradeIn-Line ➝ Outperform
4/19/2023Needham & Company LLCReiterated RatingBuy$23.00
4/5/2023Needham & Company LLCReiterated RatingBuy$23.00
3/13/2023Craig HallumInitiated CoverageBuy$21.00
3/1/2023BMO Capital MarketsLower TargetOutperform$35.00 ➝ $30.00
2/10/2023BMO Capital MarketsInitiated CoverageBuy$35.00
2/10/2023Needham & Company LLCLower TargetBuy$25.00 ➝ $23.00
1/10/2023GuggenheimLower Target$30.00 ➝ $22.00
1/4/2023Needham & Company LLCLower TargetBuy$38.00 ➝ $25.00
1/4/2023BMO Capital MarketsLower TargetOutperform$38.00 ➝ $35.00
11/14/2022BMO Capital MarketsLower TargetOutperform$45.00 ➝ $38.00
11/11/2022GuggenheimLower TargetBuy$42.00 ➝ $30.00
10/20/2022Jefferies Financial GroupInitiated CoverageBuy$16.00
8/3/2022BMO Capital MarketsLower Target$54.00 ➝ $45.00
8/3/2022The Goldman Sachs GroupLower TargetNeutral$15.00 ➝ $9.00
8/3/2022Needham & Company LLCLower TargetBuy$44.00 ➝ $38.00
5/24/2022The Goldman Sachs GroupLower TargetNeutral$32.00 ➝ $15.00
10/18/2021GuggenheimBoost TargetBuy$66.00 ➝ $75.00
9/30/2021Needham & Company LLCInitiated CoverageBuy$55.00
(Data available from 8/2/2021 forward)

News Sentiment Rating

0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/4/2026
  • 1 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/3/2026
  • 1 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/5/2026
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/4/2026
  • 1 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/4/2026
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2026
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2026
  • 4 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
8/2/2026

Current Sentiment

  • 4 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Phathom Pharmaceuticals logo
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Read More

Today's Range

Now: $8.75
Low: $8.67
High: $9.49

50 Day Range

MA: $10.77
Low: $8.75
High: $12.61

52 Week Range

Now: $8.75
Low: $8.02
High: $18.31

Volume

3,311,760 shs

Average Volume

1,356,673 shs

Market Capitalization

$697.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.49

Frequently Asked Questions

What sell-side analysts currently cover shares of Phathom Pharmaceuticals?

The following equities research analysts have issued reports on Phathom Pharmaceuticals in the last twelve months: Barclays PLC, Cantor Fitzgerald, Craig Hallum, Guggenheim, HC Wainwright, Needham & Company LLC, Raymond James Financial, Inc., Stifel Nicolaus, Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for PHAT.

What is the current price target for Phathom Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Phathom Pharmaceuticals in the last year. Their average twelve-month price target is $23.43, suggesting a possible upside of 167.8%. Stifel Nicolaus has the highest price target set, predicting PHAT will reach $28.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $18.00 for Phathom Pharmaceuticals in the next year.
View the latest price targets for PHAT.

What is the current consensus analyst rating for Phathom Pharmaceuticals?

Phathom Pharmaceuticals currently has 1 sell rating, 6 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for PHAT.

What other companies compete with Phathom Pharmaceuticals?

Other companies that are similar to Phathom Pharmaceuticals include Legend Biotech, Arcus Biosciences, Alumis, Adaptive Biotechnologies and Organon & Co.. Learn More about companies similar to Phathom Pharmaceuticals.

How do I contact Phathom Pharmaceuticals' investor relations team?

Phathom Pharmaceuticals' physical mailing address is 100 CAMPUS DRIVE SUITE 102, FLORHAM PARK NJ, 07932. The company's listed phone number is 877-742-8466 and its investor relations email address is [email protected]. The official website for Phathom Pharmaceuticals is www.phathompharma.com. Learn More about contacing Phathom Pharmaceuticals investor relations.